

September 1, 2025

SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director,
President and Chief Executive Officer
Noritaka Narimiya
Executive Corporate Officer and Chief Financial Officer
TEL: +81-3-5472-1125

**Notice Regarding the Monthly Exercise Status of the 58th and 65th Stock Acquisition Rights
(with Exercise Price Adjustment Clause) Issued through Third-Party Allotment**

SymBio Pharmaceuticals Limited (the “Company”) hereby announces the monthly exercise status for August 2025 of the 58th Stock Acquisition Rights, which were allotted to CVI Investments, Inc. and issued on June 1, 2022, and the 65th Stock Acquisition Rights, which were allotted to EVO FUND and issued on August 12, 2025 (collectively or individually referred to as the “Stock Acquisition Rights”).

The Company is disclosing monthly exercise status for the 58th Stock Acquisition Rights, as these rights are now deemed to fall under MSCBs, etc. as defined in Article 410 of the Securities Listing Regulations established by the Tokyo Stock Exchange, following the issuance of the 65th through 67th Stock Acquisition Rights on August 12, 2025.

The exercise prices of the 66th and 67th Stock Acquisition Rights issued to EVO FUND on August 12, 2025, have been revised in line with the exercise price of the 65th Stock Acquisition Rights, as noted in “6. Exercise Status in the Relevant Month” below. However, under the purchase agreement with EVO FUND, the 66th Stock Acquisition Rights cannot, in principle, be exercised until August 13, 2026, and the 67th Stock Acquisition Rights until August 13, 2027. Therefore, the Company is omitting the disclosure of their monthly exercise status.

1.	Name of Stock Acquisition Rights	(1) SymBio Pharmaceuticals Limited's 65th Stock Acquisition Rights	(2) SymBio Pharmaceuticals Limited's 58th Stock Acquisition Rights
2.	Number of Shares Delivered in the Relevant Month	760,000 shares	0 shares
3.	Number of Stock Acquisition Rights Exercised in the Relevant Month, and Ratio of Exercised to Total Issued Stock Acquisition Rights	7,600 rights (Ratio to total number of Stock Acquisition Rights issued 200,000: 3.8%)	0 rights (Ratio to total number of Stock Acquisition Rights issued [20,000]: 0%)
4.	Number of Unexercised Stock Acquisition Rights as of August 12, 2025	200,000 rights	20,000 rights
5.	Number of Unexercised Stock Acquisition Rights as of the End of the Relevant Month	192,400 rights	20,000 rights

* The ratio of exercised to total issued Stock Acquisition Rights is rounded to one decimal place.

6. Exercise Status in the Relevant Month

(1) SymBio Pharmaceuticals Limited's 65th Stock Acquisition Rights

Exercise Date	Number of Shares Delivered		Exercise Price (Yen)	Number of Stock Acquisition Rights Exercised (Rights)
	Newly Issued Shares	Transferred Treasury Shares		
August 13 (Wed)	-	-	168	-
August 14 (Thu)	-	-	160	-
August 15 (Fri)	-	-	160	-
August 18 (Mon)	100,000	-	154	1,000
August 19 (Tue)	70,000	-	154	700
August 20 (Wed)	100,000	-	153	1,000
August 21 (Thu)	70,000	-	153	700
August 22 (Fri)	50,000	-	153	500
August 25 (Mon)	50,000	-	153	500
August 26 (Tue)	100,000	-	152	1,000
August 27 (Wed)	220,000	-	152	2,200
August 28 (Thu)	-	-	151	-
August 29 (Fri)	-	-	151	-

* Number of shares issued as of August 12: 48,855,455 shares (including 90,964 treasury shares)

(2) SymBio Pharmaceuticals Limited's 58th Stock Acquisition Rights

Exercise Date	Number of Shares Delivered		Exercise Price (Yen)	Number of Stock Acquisition Rights Exercised (Rights)
	Newly Issued Shares	Transferred Treasury Shares		
August 12 (Tue)	-	-	155	-
August 13 (Wed)	-	-	155	-
August 14 (Thu)	-	-	155	-
August 15 (Fri)	-	-	155	-
August 18 (Mon)	-	-	154	-
August 19 (Tue)	-	-	154	-
August 20 (Wed)	-	-	153	-
August 21 (Thu)	-	-	153	-
August 22 (Fri)	-	-	153	-
August 25 (Mon)	-	-	153	-
August 26 (Tue)	-	-	152	-
August 27 (Wed)	-	-	152	-
August 28 (Thu)	-	-	151	-
August 29 (Fri)	-	-	151	-

* Number of shares issued as of August 12: 48,855,455 shares (including 90,964 treasury shares).

7. Status of Exercise Restrictions (Status of Compliance with Exercise Restrictions under Article 434 of the Listing Regulations)

(i) Total Number of Shares Delivered (All Series Combined)	(ii) Number of Listed Shares as of Payment Date of Issuance	(iii) Exercise Ratio Subject to Exercise Restrictions ((i) / (ii))
760,000 shares	48,855,455 shares	1.6%

* The exercise ratio subject to exercise restrictions is rounded to one decimal place.

For further details regarding these Stock Acquisition Rights, please refer to the “Notice of the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party allotment” announced on May 16, 2022, the “Notice Concerning the Treatment of the 58th Stock Acquisition Rights in Light of the Issuance of the 65th to 67th Stock Acquisition Rights” announced on July 22, 2025, and the “Notice Regarding the Issuance of the 65th to 67th Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment and the Execution of a Purchase Agreement (Commit Issue) for the 1st Unsecured Straight Bonds and Stock Acquisition Rights” announced on July 22, 2025.